Clinical Trial Update: An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating the safety of interferon gamma-1b in patients with idiopathic pulmonary fibrosis; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Drugs mentioned

• Interferon-gamma 1b (interferon gamma-1b)

Snippet

Sponsor: InterMune | Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis | Phase 3 | Status: TERMINATED